ClinicalTrials.gg
CompletedNCT02457221Updated Nov 1, 2024

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis

A Phase 3 interventional study of Tacrolimus capsules and Cyclophosphamide injections in Lupus Nephritis, sponsored by Astellas Pharma China, Inc.. Completed at 35 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing tacrolimus in Lupus Nephritis — 1 open to participants now, 1 under way, none of them phase 3. Tacrolimus · Lupus Nephritis.

Enrollment
2nd of 16
314 · median 73
Started
2015
with 1 other
Phase 3
7 of 16
none open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
Astellas Pharma China, Inc.

Among the 16 studies testing tacrolimus in Lupus Nephritis, this one is the 2nd largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 14th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

1 of the 16 studies testing tacrolimus in Lupus Nephritis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing tacrolimus in Lupus Nephritis, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of Tacrolimus capsules for induction remission in patients with lupus nephritis, and compare the efficacy and safety with Cyclophosphamide injections.

Read the detailed description

This is a randomized, open, 1:1 parallel controlled, multi-center, non-inferiority clinical study.

03

Conditions studied

  • Lupus Nephritis

Browse trials for

Keywords

  • Tacrolimus
  • Cyclophosphamide
  • Prograf
  • lupus nephritis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18.5≤ (BMI) \<27;
  • Diagnosed as systemic lupus erythematosus (based on American Rheumatism Association Diagnostic Criteria 1997)
  • Diagnosed as III, IV, V, III + V, IV + V lupus nephritis (according to the LN classification in International Society of Nephrology and Renal Pathology Society (ISN/RPS) 2003) within 24 weeks before enrollment with renal ;
  • 24-hour urine protein ≥ 1.5g, Scr\<260umol/L (or 3mg/dL)

Exclusion criteria

Exclusion Criteria:

  • Class II or VI lupus nephritis or renal chronic index (CI) > 3 or with TMA;
  • Received (mycophenolate mofetil (MMF), cyclosporine, methotrexate, mechlorethamine, chlorambucil, tripterygium preparations, leflunomide etc.) treatment with a duration of more than one week within 30 days prior to enrollment;
  • Received tacrolimus (except for topical use) or cyclophosphamide treatment within 30 days prior to enrollment;
  • Received a course of methylprednisolone (MP) pulse therapy or gamma globulin treatment or plasma exchange within 30 days prior to enrollment;
  • Patients with history of allergies to tacrolimus, cyclophosphamide or methylprednisolone;
  • Pregnancy, lactation or patient unwilling to take measures;
  • Patients with estimated maintenance dialysis for more than eight weeks; or dialysis for more than two weeks prior to entering observation;
  • Patients received kidney transplantation or plan to have kidney transplantation recently;
  • Serum creatinine (Scr) ≥260umol/L (or 3mg/dL) or rate (Ccr) \< 30ml/(min.1.73m2); according to Cockcroft-Gault formula: Ccr (ml/sec) = [(140- age)× Weight (kg)] × K / [72×Scr (umol/L) ×0.6786], Female K = 0.85, Male K = 1.0;
  • Patients suffering from liver dysfunction ( (AST) or alanine aminotransferase (ALT) more than 3 times the lab value) or more than 3 times the upper limit of normal lab value;
  • Patients diagnosed with diabetes;
  • History of gastrointestinal bleeding or pancreatitis within 3 months;
  • Uncontrollable hyperkalemia after dietary therapy or reduction of potassium treatment (exceed the upper limit of normal lab value);
  • Patients suffering from lupus pneumonia or lung injury;
  • Patients with anemia ( \<7g/dl) or bone marrow suppression (WBC \<3.0×109/L, and/or neutrophils \<1.5×109/L, and/or \<50×109/L) not secondary to systemic lupus erythematosus;
  • With congenital heart disease, arrhythmia, heart failure or other severe cardiovascular diseases;
  • With hypertension (defined as blood pressure still exceeds 180/110 mmHg despite taking three different types of antihypertensive drugs [one of them is diuretic] simultaneously);
  • Patients with recurrent tumors within 5 years;
  • Severe infection that requires intravenous antibiotics within 2 weeks prior to enrollment;
  • Patients with infection of virus or virus; patients with active tuberculosis; patients with severe immunodeficiency diseases (including active cytomegalovirus infection (positive CMV IgM antibody), or (HIV) infection, etc.);
  • Patients with lupus encephalopathy or other life-threatening complication of systemic lupus erythematosus;
  • Patients participated in other clinical trials within three months before enrollment
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    Tacrolimus group

    Tacrolimus capsules + steroid

    Drug: Tacrolimus capsules · Drug: Prednisone

  • Active comparator
    Cyclophosphamide group

    Cyclophosphamide injections + steroid

    Drug: Cyclophosphamide injections · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Remission rate (complete remission + partial remission)

    complete remission: urine protein \< 0.5g/24hr, and serum albumin≥3.5g/dl, and stable renal function (Scr increase ≤ 15% baseline value) partial remission: urine protein 0.5-3.5g/24hr (≥ 0.5 g/24hr and \< 3.5 g/24hr), and urine protein decreased by \>50% comparing with the baseline, and serum albumin ≥ 3.0g/dl, and stable renal function (Scr increase ≤ 15% baseline value)

    Time frame: at 24 weeks

Secondary outcomes

  1. 24-hour urine protein

    Time frame: at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24

  2. Change of 24-hour urine protein from baseline

    Time frame: at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24

  3. Serum albumin

    Time frame: at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24

  4. Change of Serum albumin from baseline

    Time frame: at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24

  5. Serum creatinine

    Time frame: at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24

  6. Change of Serum creatinine from baseline

    Time frame: at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24

  7. eGFR comparing with baseline

    eGFR: Estimated Glomerular Filtration Rate

    Time frame: at Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24

  8. Percentage of patients converted to other immunosuppressive therapy

    Time frame: during 24 weeks

  9. Percentage of patients with serum creatinine rising to two times of the baseline

    Time frame: during 24 weeks

  10. Percentage of patients with dsDNA and ANA converting from positive to negative

    ANA: Antinuclear Antibody

    Time frame: during 24 weeks

  11. SLE-DAI

    SLE-DAI: Systemic Lupus Erythematosus - Disease Activity Index

    Time frame: at Week 4, 12 and 24

  12. Immune parameters assessed by ESR, C3, C4 and dsDNA

    ESR: Erythrocyte Sedimentation Rate, C3, C4: Complement C3, C4, dsDNA: Anti-Double-Stranded DNA Antibodies

    Time frame: at Week 4, 12 and 24

  13. Change of SLE-DAI from baseline

    Time frame: at Week 4, 12 and 24

  14. Change of immune parameters from baseline

    Time frame: at Week 4, 12 and 24

  15. Renal biopsy AI (Active Index)

    Time frame: at Week 24

  16. CI (Chronic Index)

    Time frame: at Week 24

  17. Change of Renal biopsy AI (Active Index) from baseline

    Time frame: at Week 24

  18. Change of CI (Chronic Index) from baseline

    Time frame: at Week 24

07

Study locations

35 sites
  • Site CN00043
    Hefei, Anhui, China
  • Site CN00030
    Beijing, Beijing, China
  • Site CN00034
    Beijing, Beijing, China
  • Site CN00041
    Xiamen, Fujian, China
  • Site CN00056
    Guangzhou, Guangdong, China
  • Site CN00017
    Shenzhen, Guangdong, China
  • Site CN00045
    Liuzhou, Guangxi, China
  • Site CN00037
    Nanning, Guangxi, China
  • Site CN00038
    Nanning, Guangxi, China
  • Site CN00020
    Shijiazhuang, Hebei, China
  • Site CN00047
    Shijiazhuang, Hebei, China
  • Site CN00028
    Zhengzhou, Henan, China
  • Site CN00023
    Wuhan, Hubei, China
  • Site CN00024
    Wuhan, Hubei, China
  • Site CN00027
    Changsha, Hunan, China
  • Site CN00050
    Changsha, Hunan, China
  • Site CN00012
    Nanjing, Jiangsu, China
  • Site CN00013
    Nanjing, Jiangsu, China
  • Site CN00025
    Nanjing, Jiangsu, China
  • Site CN00049
    Wuxi, Jiangsu, China
  • Site CN00026
    Changchun, Jilin, China
  • Site CN00042
    Changchun, Jilin, China
  • Site CN00005
    Dalian, Liaoning, China
  • Site CN00018
    Shenyang, Liaoning, China
  • Site CN00019
    Shenyang, Liaoning, China
  • Site CN00032
    Qingdao, Shandong, China
  • Site CN00001
    Shanghai, Shanghai, China
  • Site CN00014
    Shanghai, Shanghai, China
  • Site CN00015
    Shanghai, Shanghai, China
  • Site CN00052
    Taiyuan, Shanxi, China
  • Site CN00002
    Chengdu, Sichuan, China
  • Site CN00003
    Chengdu, Sichuan, China
  • Site CN00021
    Tianjin, Tianjin, China
  • Site CN00044
    Wulumuqi, Xinjiang, China
  • Site CN00010
    Hangzhou, Zhejiang, China
08

References and documents

Publications

  • Zheng Z, Zhang H, Peng X, Zhang C, Xing C, Xu G, Fu P, Ni Z, Chen J, Xu Z, Zhao MH, Li S, Huang X, Miao L, Chen X, Liu B, He Y, Li J, Liu L, Kadeerbai H, Liu Z, Liu Z. Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial. JAMA Netw Open. 2022 Mar 1;5(3):e224492. doi: 10.1001/jamanetworkopen.2022.4492. PubMed 35353167 ↗

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2015 to primary completion in Sep 2018, 42 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2015
First posted
May 29, 2015
StartActual
Mar 10, 2015
Primary completionActual
Sep 10, 2018
CompletionActual
Sep 10, 2018
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02457221
Responsible party
Sponsor
First posted
May 29, 2015
Start date
Mar 10, 2015
Primary completion
Sep 10, 2018
Completion
Sep 10, 2018
Last update
Nov 1, 2024

Study contacts

Medical Director
study director · Astellas Pharma China, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion